Finerenone – a new option to reduce the risk of progression of renal and cardiovascular damage in patients with chronic kidney disease and type 2 diabetes mellitus

Czech version

Authors: Viera Doničová
Authors‘ workplace: HUMAN CARE s. r. o., Košice
Published in: Diab Obez 2022; 22(44): 129-132
Category: News

Overview

Diabetes mellitus type 2 is a serious illness, which is a cause of death in about 44 %. Every 5 seconds dies, one patient from diabetes in the world. The risk of death in patients with diabetes and CKD is three times higher in comparison to the healthy population. One of the main pathophysiological mechanism of deterioration of the renal and cardiovascular system is the overstimulation of mineralocorticoid receptors. New treatment and molecule of the nonsteroidal, selective antagonist of the mineralocorticoid receptor finerenone significantly decrease the progression of CKD even in advanced stages, as well as the cardiovascular events. These data are achieved in two clinical trials: FIDELO-DKD and FIGARO-DKD, and subsequent metanalysis of these data in FIDELITY analysis.

Keywords:

chronic kidney disease (CKD) – albumin creatinine ratio in urine (UACR) – antagonist of the mineralocorticoid receptor (MRA) – arterial hypertension (AH) – blockade of mineralocorticoid receptors (BMR) – cardiovascular complication (CVC) – cardiovascular risk (CVR) – diabetes mellitus (DM) – glomerular hypertension (GH) – GLP-1RA (agonist of GLP-1 receptor) – heart failure (HF) – mineralocorticoid receptors (MR) – renal dead (RD) – renin–angiotensin system (RAS) – sodium-glucose cotransporter-2 inhibitors (SGLT2i)

Sources

1. IDF Diabetes Atlas. 9th ed. Dostupné z WWW: <https://diabetesatlas.org/en/>.

2. Afkarian M, Sachs MC, Bryan Kestenbaum B et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol 2013; 24(2): 302–308. Dostupné z DOI: <http://dx.doi.org/10.1681/ASN.2012070718>.

3. Wu B, Bell K, Stanford A et al. Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns-NHANES 2007–2012. BMJ Open Diabetes Res Care 2016; 4: 1–11. Dostupné z DOI: <http://dx.doi.org/10.1136/bmjdrc-2015–000154>.

4. Buonafine M, Bonnard B, Jaisser F. Mineralocorticoid Receptor and Cardiovascular Disease. Am J Hypertension 2018; 31(11): 1165–1174. Dostupné z DOI: <http://dx.doi.org/10.1093/ajh/hpy120>.

5. Kolkhof P, Jaisser F, Kim S-Y et al. Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside. Handb Exp Pharmacol 2017; 243: 271–305. Dostupné z DOI: <http://dx.doi.org/10.1007/164_2016_76>.

6. Bauersachs J, Jaisser F, Toto R. Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases. Hypertension 2015; 65(2): 257–263.Dostupné z DOI: <http://dx.doi.org/10.1161/HYPERTENSIONAHA.114.04488>.

7. Gomez-Sanchez E, Gomez-Sanchez CE. The multifaceted mineralocorticoid receptor. Compr Physiol 2014; 4(3): 965–994. Dostupné z DOI: <http://dx.doi.org/10.1002/cphy.c130044>.

8. Brown NJ. Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nat Rev Nephrol 2013; 9(9): 459–469. Dostupné z DOI: <http://dx.doi.org/10.1038/nrneph.2013.110>.

9. Biwer LA, Wallingford MC, Jaffe IZ. Vascular Mineralocorticoid Receptor: Evolutionary Mediator of Wound Healing Turned Harmful by Our Modern Lifestyle. Am J Hypertension 2019; 32(2): 123–134. Dostupné z DOI: <http://dx.doi.org/10.1093/ajh/hpy158>.

10. Barrera-Chimal J, Girerd S, Jaisser F. Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis. Kidney Int 2019; 96(2): 302–319. Dostupné z DOI: <http://dx.doi.org/10.1016/j.kint.2019.02.030>.

11. van de Heijden CD, Deinum J, Joosten LA et al. The mineralocorticoid receptor as a modulator of innate immunity and atherosclerosis. Cardiovasc Res 2018; 114(7): 944–953. Dostupné z DOI: <http://dx.doi.org/10.1093/cvr/cvy092>.

12. Bakris GL, Agarwal R, Anker SD et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 2020; 383(23): 2219–2229. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2025845>.

13. Kerendia. Súhrn charakteristických vlastností lieku. EMA Europa 2022. Dostupné z WWW: <https://www.ema.europa.eu/en/documents/product-information/kerendia-epar-product-information_sk.pdf>.

14. Pitt B, Filippatos G, Agarwal R et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med 2021; 385(24): 2252–2263. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2110956>.

15. Agarwal R, Filippatos G, Pitt B et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J 2022; 43(6): 474–484. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehab777>.

16. Standards of Medical Care in Diabetes – 2022: 11. Chronic Kidney Disease and Risk Management. Diabetes Care 2022; 45(Suppl 1): S175–S184. Dostupné z DOI: <http://dx.doi.org/10.2337/dc22-S011>. Erratum in Erratum: Standards of Medical Care in Diabetes – 2022: 11. Chronic Kidney Disease and Risk Management. Diabetes Care 2022; 45(3): 758. Dostupné z DOI: <http://dx.doi.org/10.2337/dc22-er03>.

17. Blonde L, Umpierrez GE, Sethu Reddy S et al. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan – 2022 Update. Endocr Pract 2022; 28(10): 923–104. Dostupné z DOI: <https://doi.org/10.1016/j.eprac.2022.08.002>.

18. de Boer IH, Khunti K; Sadusky T et al. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care 2022. Dostupné z DOI: <https://doi.org/10.2337/dci22–0027>.